A Phase IIIb/IV Safety Trial of Flat Dose Nivolumab in Combination with Ipilimumab in Participants with Advanced Malignancies
Research Grant
Awarded By
Bristol-Myers Squibb Company
Start Date
January 17, 2017
End Date
October 31, 2022
Awarded By
Bristol-Myers Squibb Company
Start Date
January 17, 2017
End Date
October 31, 2022